Roche Holding AG (OTCMKTS:RHHBY) Shares Acquired by Bard Financial Services Inc.

Bard Financial Services Inc. grew its stake in shares of Roche Holding AG (OTCMKTS:RHHBY) by 37.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 110,850 shares of the company’s stock after acquiring an additional 30,350 shares during the quarter. Bard Financial Services Inc.’s holdings in Roche were worth $3,866,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Altrius Capital Management Inc increased its position in shares of Roche by 6.0% in the 2nd quarter. Altrius Capital Management Inc now owns 224,804 shares of the company’s stock worth $7,794,000 after purchasing an additional 12,646 shares during the last quarter. Verity Asset Management Inc. acquired a new position in shares of Roche during the third quarter valued at $253,000. IHT Wealth Management LLC acquired a new position in Roche during the 3rd quarter valued at about $236,000. AlphaMark Advisors LLC acquired a new stake in Roche in the 3rd quarter valued at approximately $149,000. Finally, Diversified Trust Co grew its stake in shares of Roche by 6.4% in the third quarter. Diversified Trust Co now owns 59,742 shares of the company’s stock worth $2,396,000 after purchasing an additional 3,613 shares in the last quarter.

Roche Trading Up 0.7 %

RHHBY traded up $0.24 on Monday, hitting $35.18. 1,384,172 shares of the stock were exchanged, compared to its average volume of 1,047,586. The business has a 50-day moving average of $36.28 and a two-hundred day moving average of $37.96. Roche Holding AG has a 12 month low of $29.20 and a 12 month high of $42.43.

Analyst Upgrades and Downgrades

RHHBY has been the topic of several analyst reports. Bank of America upgraded shares of Roche from a “neutral” rating to a “buy” rating in a research note on Friday, September 13th. Deutsche Bank Aktiengesellschaft downgraded Roche from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the stock. According to MarketBeat, Roche presently has a consensus rating of “Hold”.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.